DIAGNOSTIC POSSIBILITIES OF RESEARCHING THE STATE OF NEUROMUSCULAR TRANSMISSION IN PATIENTS WITH MYASTHENIA AND MYASTHENIC SINDROMES

Aim. To study and analyse diagnostic meaningfulness of the different electromyographic methods applied for the exposure of violations of neuromuscular transmission transmission.

Materials and methods. There are many methods of the researching of the condition of neuro muscular transfer, each of them carries the certain diagnostic importance allowing to define character of a lesion of a neuro muscular synapse, to tap mechanisms of its development not only in clinically affected muscles, but also intact ones, and also at an early stage of a disease, at local forms of a myasthenia. The research of the condition of neuromuscular transmission was carried out with the use of the following electromyographic techniques: stimulation electroneuromyography (ENMG), the decrement test, the jitter-phenomenon, research of density of a single muscle fiber.

Results. The result of the analysis of electromiographic diagnostic opportunities of researching the condition of neuro muscle fiber development is the developing of the clinic-instrumental algorithm of inspection of patients with a myasthenia.

Conclusion. The different neurophysiological methods of study of the state of neuromuscular transmission carry certain diagnostic meaningfulness. Advantages of separate electromyographic methods are shown: research of initial amplitude of M-answer, decrement-test, джиттер-phenomenon. The indexes of ENMG-tests are analysed in detail-tests, and also their change at violation of neuromuscular transmission for patients with myasthenia gravis and myasthenic syndromes.

1. Алчинова И.Б., Е.Н. Яковенко, Д.В. Сиднев и др. Сравнительный анализ информативности радиоиммунологического определения антител к ацетилхолиновому рецептору и лазерной корреляционной спектроскопии при миастении. Журнал неврологии и психиатрии имени С.С. Корсакова. 2017; 117(2): 97-103. [Alchinova I.B., Yakovenco Е.N., Sidnev D.V., Dedaev S.Yu., Sanadze A.G., Karganov M.Y. The Comparative analysis of informing of радиоиммунологического determination of antibodies to the acetylcholine receptor and laser cross-correlation spectroscopy at myasthenia. Journal of neurology and psychiatry of the name S.S. Korsakova. 2017; 117(2): 97-103. (In Russ., English abstract). DOI: 10.17116/jnevro20171172197-103].

2. Тимуров Д.А., Санадзе А.Г. Декремент амплитуды М-ответа при низкочастотной стимуляции мышц больных миастенией и миастеническим синдромом Ламберта-Итона. Журнал неврологии и психиатрии имени С.С. Корсакова. 2017; 117(2): 93-96. [Tumurov D.А., Sanadze А.G. Decrement of amplitude of М of answer at low-frequency stimulation of muscles of patients миастенией and myasthenic syndrome of Lambert- Eaton. Journal of neurology and psychiatry of the name S.S. Korsakova. 2017; 117(2): 93-96. (In Russ., English abstract). DOI: 10.17116/ jnevro20171172193-96].

3. Котов С.В., Сидорова О.П. Исходы и лечение миастенического криза. Журнал неврологии и психиатрии имени С.С. Корсакова. 2016; 116(1): 103-105. [Kotov S.V., Sidorova О.P. Ends and treatment of myasthenic crisis. Journal of neurology and psychiatry of the name S.S. Korsakova. 2016; 116(1): 103-105. (In Russ., English abstract). DOI: 10.17116/jnevro20161164-90].

4. Фельдман Е., Гризольд В., Рассел Дж. Лешер В. Атлас нервно-мышечных болезней, практическое руководство. Практическая медицина, 2016. [Feldman E., Grisold V., Russell J. Loescher V. Atlas of neuromuscular illnesses, practical guidance. Practical medicine, 2016. (In Russ.)].

5. Санадзе А.Г. Миастения и миастенические синдромы. Москва: ГЭОТАР-Медиа; 2017. 70-81. [Sanadze А.G. Myasthenia gravis and myasthenic syndromes. Moscow: GEOTAR-Media; 2017: 70-81. (In Russ.)].

6. Щербакова Н.И., Супонева Н.А., Шведков В.В. и др. Российский опыт успешного применения ритуксимаба при рефрактерных формах миастении гравис. Журнал нервно-мышечные болезни. 2015; 5(3): 51-53. [Shcherbakova N.I., Suponeva N.A., Shvedkov V.V. et al. Positive experience of the usage of Rituximab in management of refractory myasthenia gravis in Russia. Journal Neuromuscular Diseases. 2015; 5(3): 50-61. (In Russ., English abstract), DOI: 10.17650/2222-8721-2015-5-3-50-61].

7. Чемордаков И.А., Куташов В.А. Современный взгляд на клинику и диагностику миастении. Журнал Молодой ученый. 2015; 11: 311-313. [Chemordakov I.A, Kutashov V.A. Modern view of the clinic and diagnosis of myasthenia gravis. Journal of Young Scientist. 2015; 11: 311-313. (In Russ., English abstract)].

8. Гасымлы Э.Д., Исаева Н.В., Прокопенко С.В. и др. Эпидемиологические и клинические особенности миастении на территории Красноярского края. Журнал нервно-мышечные болезни. 2017; 7(4): 33-38. [Gasymly E.D., Isaeva N.V., Prokopenko S.V. et al. Epidemiological and clinical characteristics of myasthenia in the Krasnoyarsk region. Journal Neuromuscular Diseases. 2017; 7(4): 33-38. (In Russ., English abstract). DOI: 10.17650/2222-8721-2017-7-4-33-38].

9. Климова Е.М., Дроздова Л.А., Нечитайло П.Е. и др. Диагностические критерии осложненного течения миастении у больных после тимэктомии. Лабораторная диагностика. 2013; 3(65): 14-19. [Klimova E.M., Drozdova L.A., Nechitailo P.E. et al. Diagnostic criteria of complicated myasthenia flow in patients after thymectomy. Laboratory diagnostics. 2013; 3(65): 14-19. (In Russ., English abstract)].

10. Агафонов Б.В., Котов С.В., Сидорова О.П. Миастения и врожденные миастенические синдромы. Москва: Медицинское информационное агентство; 2013. 223 с. [Agafonov B.V., Kotov S.V., Sidorova O.P. Myasthenia and congenital myasthenic syndromes. Moscow: Meditsinskoe informatsionnoe agentstvo; 2013. 223 p. (In Russ.)].

11. Николаев С.Г. Электромиография: клинический практикум. Иваново: ПрессСто; 2013. 163-197. [Nikolaev S.G. Electromyography: clinical practice. Ivanovo: PressSto; 2013. 163-197. (In Russ.)].

12. Смолин А.И. современные аспекты клиники и диагностики миастении. Сибирский медицинский журнал. 2013; 3: 1214. [Smolin A.I. modern aspects of the clinic and diagnosis of myasthenia gravis. Siberian Medical Journal. 2013; 3: 12-14. (In Russ.)].

13. Конькова Д.Ю., Карнаух В.Н., Дулеба А.П. Клинический опыт ведения кризов у больных миастенией в Амурской области. Журнал Нервно-мышечные болезни. 2016; 6(2): 35-40. DOI: 10.17650/2222-8721-2016-6-2-35-40. [Kon’kova D.Y., Karnaukh V.N., Duleba A.P. Clinical experience of myasthenic crisis management in Amur region. Journal Neuromuscular Diseases. 2016; 6(2): 35-40. (In Russ., English abstract), DOI: 10.17650/2222-87212016-6-2-35-40].

14. Быков Ю.Н., Смолин А.И. Лечение и реабилитация больных миастенией. Сибирский медицинский журнал. 2013; 4: 7-9. [Bykov Y.N., Smolin A.I. Treatment and rehabilitation of patients with myasthenia gravis. Siberian Medical Journal. 2013; 4: 7-9. (In Russ., English abstract)].

15. Санадзе А.Г., Касаткина Л.Ф. Клиническая электромиография для практических неврологов. Москва: ГЭОТАР-Медиа; 2015. 63 c. [Sanadze А.G., Kasatkina L.F. Clinical electromyography for practical neurologists. Moscow: GEOTAR-Media; 2015. 63 p. (In Russ.)].

16. Дедаев С.И. Антитела к аутоантигенным мишеням при миастении и их значение в клинической практике. Нервно-мышечные болезни. 2014; (2): 6-15. DOI: 10.17650/2222-87212014-0-2-6-15. [Dedaev S.I. Antibodies to autoantigen targets in myasthenia and their value in clinical practice. Journal Neuromuscular Diseases. 2014; (2): 6-15. (In Russ., English abstract). DOI: 10.17650/2222-8721-2014-0-2-6-15].

17. Алексеева Т.М., Косачев В.Д., Халмурзина А.Н. Клинико-иммунологические особенности миастении и подходы к ее терапии у лиц пожилого возраста (обзор литературы). Нервномышечные болезни. 2016; 6(3): 10-16. DOI: 10.17650/22228721-2016-6-3-10-16. [Alekseeva T.M., Kosachev V.D., Khalmurzina A.N. Clinical and immunological features and treatment of myasthenia gravis in the elderly (review). Journal Neuromuscular Diseases. 2016; 6(3): 10-16. (In Russ., English abstract), DOI: 10.17650/2222-8721-2016-6-3-10-16].

18. Лобзин С.В. Миастения: диагностика и лечение. СПб.: СпецЛит; 2015. 160 с. [Lobzin S.V. Myasthenia: diagnosis and treatment. Saint Petersburg: SpetsLit; 2015. 160 p. (In Russ.)].

19. Щербакова Н.И., Пирадов М.А., Павлова Е.М. и др. Причины, факторы риска, клинические предикторы развития кризов у больных миастенией. Неврологический журнал. 2013; 2: 11-19. [Shcherbakova N.I., Piradov M.A., Pavlova E.M.et al. The causes, risk factors and predictors of myasthenia gravis crisis. Neurological Journal. 2013; 2: 11-19. (In Russ.)].

20. Fulop T., Witkowski J.M., Pawelec G.et al. On the immunological theory of aging. Interdiscip Top Gerontol. 2014: 163-76. DOI: 10.1159/000358904.

21. Donald B. Sanders D., Gil I. et al. International consensus guidance for management of myasthenia gravis: Executive summary. Journal Neurology. 2016: 87(4): 419-425.

22. Nagappa M., Netravathi M., Taly A.B. et al. Long-term efficacy and limitations of cyclophosphamide in myasthenia gravis. Journal Clinical Neuroscience. 2014; 21(11): 1909-14. DOI: 10.1016/j.jocn.2014.03.019.

23. Nakamura S., Kaneko S., Shinde A. et al. Prednisolone-sparing effect of cyclosporin A therapy for very elderly patients with myasthenia gravis. Journal Neuromuscular Disordes. 2013: 176-9. DOI: 10.1016/j.nmd.2012.11.003.

24. Bryant A., Atkins H., Pringle C.E. et al. Myasthenia gravis treated with autologous hematopoietic stem cell transplantation. JAMA Neurology. 2016: 652-658. DOI: 10.1001/jamaneurol.2016.0113.

25. Uzawa A., Kawaguchi N., Kanai T. et al. Two-year outcome of thymectomy in nonthymomatous late-onset myasthenia gravis. Journal Neurology. 2015: 1019-23. DOI: 10.1007/s00415-015-7673.

26. Murai H., Yamashita N., Watanabe M. et al. Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. Journal Neurological science. 2012: 97-102. DOI: 10.1016/j.jns.2011.03.004.

27. Strober J., Cowan M.J., Horn B.N. Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis. Arch Neurology. 2009: 659-61. DOI: 10.1001/ archneurol.2009.28.

28. Basic-Jukic N., Brunetta B., Kes P. Plasma exchange in elderly patients. Ther Apher Dial. 2010: 161-5. DOI: 10.1111/j.17449987.2009.00793.

29. Barnett C., Bril V., Kapral M. Development and validation of the Myasthenia Gravis Impairment Index. Journal Neurology. 2016: 879-886. DOI: 10.1212/WNL.0000000000002971.

30. Berrih-Aknin S., Frenkian-Cuvelier M., Eymard B. Diagnostic and clinical classification of autoimmune myasthenia gravis. Journal Autoimmun. 2014: 143-148. DOI: 10.1016/j.jaut.2014.01.003.

31. Gilhus N.E., Verschuuren J.J. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurology. 2015: 1023-36. DOI: 10.1016/S1474-4422(15)00145-3.

32. Psaridi-Linardaki., Trakas N., Mamalaki A. et al. Specific immunoadsorption of theantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor alpha-subunit: Development of an antigen-specific therapeuticstrategy. Neuroimmunology. 2005: 183-191.

33. Godoy D.A., Mello L.J., Masotti L. et al. Myasthenic patients in crisis an update of the management in Neurointensive Care Unit. Arq Neuropsiquiatr. 2013: 627-39.DOI: 10.1590/0004282X20130108.

34. Sieb J.P. Myasthenia gravis: an update for the clinician. Clin Exp Immunol. 2014: 408-18.

35. Vincent A., Newsom-Davis J., Newton P. et al. Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis. Neurology. 2000: 1276-1282.

36. Vincent A., Whiting P.J., Schluep M. et al. Antibody heterogeneity and specificity in myasthenia gravis. Ann. N.Y. Academy of Sciences. 2003: 106-120.

37. Burden S.J., Yumoto N., Zhang W. The role of MuSK in synapse formation and neuromuscular disease. Cold Spring Harb Perspect Biol. 2013: a009167.

38. Chaudhuri A., Behanq P.O. Myasthenic crisis. Journal Medicine. 2009; 102: 97-107.DOI: 10.1093/qjmed/hcn152.

39. Lisak R.P., Ragheb S. The role of B cellactivating factor in autoimmune myasthenia gravis. Ann New York. Academy of Sciens. 2012: 60-7.

40. Gajdos P., Tranchant C., Clair B. et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurology. 2005; 62: 1689-1693.

41. Jaretzki A.III, Barohn R.J., Ernstoff R.M. et al. Myasthenia gravis: recommendation for clinical research standards. Torac Surgery. 2000: 327-334.

42. Plested C.P., Tang T., Spreadbury I. et al. AChR phosphorylation and indirect inhibition of AChR function in seronegative MG. Neurology. 2002: 1672-1673.

43. Wandawart A., Kaminski H.J., Gutter G. et al. Comparative analysis of therapeutic options used for myasthenia gravis. Ann. Neurology 2010: 797-805.

44. Romi F„ Gilhus N.E., Aarli J.A. Myasthenia gravis: disease severity and prognosis. Acta Neurol. Scand. 2006: 24-25.

45. Keung B., Robeson K.R., DiCapua D.B. et al. Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients. Journal Neurol Neurosurg Psychiatry. 2013: 1407-9.